

Noe B Mercado

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1326373/noe-b-mercado-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

4,527
citations

17
h-index

42
g-index

42
ext. papers

6,034
ext. citations

25.4
avg, IF

5.08
L-index

#	Paper	IF	Citations
37	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020 , 369, 806-811	33.3	748
36	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020 , 584, 443-449	50.4	609
35	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020 , 369, 812-817	33.3	592
34	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020 , 586, 583-588	50.4	550
33	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021 , 590, 630-634	50.4	498
32	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016 , 353, 1129-32	33.3	386
31	Vaccine protection against Zika virus from Brazil. <i>Nature</i> , 2016 , 536, 474-8	50.4	383
30	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020 , 26, 1694-1700	50.5	176
29	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018 , 563, 360-364	50.4	155
28	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	86
27	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	80
26	Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. <i>Journal of Virology</i> , 2021 ,	6.6	40
25	Low-dose Ad26.COVS protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021 , 184, 3467-3473.e11	56.2	23
24	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021 , 596, 423-427	50.4	22
23	Lack of therapeutic efficacy of an antibody to Δ n SIVmac251-infected rhesus macaques. <i>Science</i> , 2019 , 365, 1029-1033	33.3	21
22	Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice. <i>Journal of Virology</i> , 2018 , 92,	6.6	20
21	Feasibility and safety of ultrasound-guided minimally invasive autopsy in COVID-19 patients. <i>Abdominal Radiology</i> , 2021 , 46, 1263-1271	3	18

20	Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors. <i>Journal of Virology</i> , 2018 , 92,	6.6	16
19	Immunity elicited by natural infection or Ad26.COVS2 vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021 , 13, eabj3789	17.5	13
18	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020 , 183, 185-196.e14	56.2	11
17	Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. <i>Nature</i> , 2021 ,	50.4	9
16	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COVS2 vaccination predict durable protection in rhesus macaques. <i>Nature Communications</i> , 2021 , 12, 5877	17.4	9
15	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021 , 13, eabj2641	17.5	8
14	Low-Dose Ad26.COVS2 Protection Against SARS-CoV-2 Challenge in Rhesus Macaques 2021 ,		8
13	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , 2021 , 12, 1474	17.4	7
12	Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates		4
11	Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation. <i>Nature Communications</i> , 2020 , 11, 5412	17.4	3
10	A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates 2021 ,		3
9	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques.. <i>Science Advances</i> , 2022 , 8, eabl6015	14.3	3
8	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. <i>Journal of Virology</i> , 2020 , 94,	6.6	2
7	Increased IL-6 expression precedes reliable viral detection in the rhesus macaque brain during acute SIV infection. <i>JCI Insight</i> , 2021 , 6,	9.9	2
6	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2021 , JVI0159921	6.6	2
5	Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. <i>PLoS Pathogens</i> , 2021 , 17, e1009673	7.6	2
4	SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COVS2 predict durable protection in rhesus macaques		2
3	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.. <i>PLoS Biology</i> , 2022 , 20, e3001609	9.7	0

2	Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments.. <i>Veterinary Pathology</i> , 2022 , 3009858221095794	2.8	○
1	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.. <i>Npj Vaccines</i> , 2022 , 7, 53	9.5	○